Analysts at Brookline Capital Management issued their FY2024 earnings per share (EPS) estimates for shares of Y-mAbs ...

Canaccord Genuity analyst John Newman has maintained their bullish stance on YMAB stock, giving a Buy rating on December 4.Pick the best ...

Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research note ...

Fintel reports that on December 5, 2024, Brookline Capital initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a ...

Detailed price information for Y-Mabs Therapeutics Inc (YMAB-Q) from The Globe and Mail including charting and trades.

Oppenheimer initiated coverage of Y-mAbs Therapeutics (YMAB) with an Outperform rating and $23 price target The firm says its enthusiasm is centered on the company’s clinical stage SADA platform ...

In the latest quarter, 4 analysts provided ratings for Y-mAbs Therapeutics (NASDAQ:YMAB), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company ...

Across the recent three months, 5 analysts have shared their insights on Y-mAbs Therapeutics YMAB, expressing a variety of opinions spanning from bullish to bearish. The following table summarizes ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...